Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Troriluzole in Generalized Anxiety Disorder
NCT03829241Phase 3Completed
- Sponsor
- Biohaven Ltd.
- Start
- Feb 2019
- Primary completion
- Jan 2020
- Modality
- Allosteric Modulators, Orthosteric Ligands, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of troriluzole in generalized anxiety disorder (GAD), sponsored by Biohaven Ltd.. Started Feb 2019; status: completed.
02
Drugs
troriluzole
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT03829241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03829241.